ImmunityBio, Inc. (NASDAQ:IBRX) is one of the best stocks to buy in a rising market, according to Wall Street analysts. On April 9, ImmunityBio, Inc. (NASDAQ:IBRX) delivered spectacular preliminary operational outcomes for its fiscal quarter ending March 31, 2026.
Product income within the quarter was up 168% yr over yr to $44.2 million. The rise comes on the heels of ANKTIVA, an FDA-approved remedy for non-muscle invasive bladder most cancers, industrial launch. The numerous product income builds on 2025 web product income of $113 million, a 700% enhance over 2024. ImmunityBio exited the quarter with $380.9 million in money and money equivalents.
ANKTIVA is the corporate’s lead product, anticipated to solidify its income base because it has been permitted throughout 5 jurisdictions representing 34 international locations. Its continued momentum underscores rising doctor adoption and disciplined industrial execution. Following sturdy progress in 2025, ImmunityBio is targeted on scaling within the US and increasing into international markets to pursue new income streams.
ImmunityBio, Inc. (NASDAQ:IBRX) is a clinical-stage biotechnology firm targeted on creating and commercializing next-generation immunotherapies that activate a affected person’s pure killer (NK) cells and T cells to deal with cancers and infectious illnesses. Its lead FDA-approved drug, ANKTIVA (N-803), is utilized in mixture with BCG to deal with non-muscle invasive bladder most cancers (NMIBC).
Whereas we acknowledge the potential of IBRX as an funding, we imagine sure AI shares provide higher upside potential and carry much less draw back danger. Should you’re searching for a particularly undervalued AI inventory that additionally stands to learn considerably from Trump-era tariffs and the onshoring pattern, see our free report on the best short-term AI stock.
READ NEXT: 11 Best TSX Stocks to Buy According to Hedge Funds and 8 Best Australian Stocks to Buy in 2026.
Disclosure: None. Follow Insider Monkey on Google News.
